Revvity (NYSE:RVTY) Insider Maxwell Krakowiak Sells 1,631 Shares of Stock

Revvity Inc. (NYSE:RVTY) insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares in the company, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Revvity Trading Down 0.8%

NYSE:RVTY traded down $1.08 during mid-day trading on Wednesday, hitting $142.23. 2,244,322 shares of the company’s stock were exchanged, compared to its average volume of 1,470,828. The company has a 50 day simple moving average of $121.92 and a 200-day simple moving average of $105.43. The firm has a market capitalization of $15.87 billion, a P/E ratio of 67.73, a PEG ratio of 2.61 and a beta of 1.09. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $149.52. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last announced its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. During the same period in the prior year, the business posted $1.18 earnings per share. The firm’s revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts expect that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Institutional Investors Weigh In On Revvity

Several large investors have recently modified their holdings of the stock. EdgePoint Investment Group Inc. raised its stake in shares of Revvity by 3.1% in the first quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after buying an additional 265,204 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Revvity during the second quarter worth $961,017,000. Janus Henderson Group PLC raised its stake in shares of Revvity by 2.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock valued at $731,386,000 after purchasing an additional 186,956 shares during the period. BlackRock Inc. purchased a new position in Revvity during the 2nd quarter valued at about $852,070,000. Finally, State Street Corp boosted its position in shares of Revvity by 0.8% in the second quarter. State Street Corp now owns 4,342,739 shares of the company’s stock valued at $483,173,000 after acquiring an additional 32,426 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on RVTY shares. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. UBS Group initiated coverage on Revvity in a research note on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price objective on the stock. Wolfe Research started coverage on shares of Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Finally, Evercore reissued an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $116.57.

About Revvity

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.